Zentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site

Prague (ots/PRNewswire) - Zentiva Group announces the completion of its
acquisition of a manufacturing site in Ankleshwar, India, from Sanofi. The
finalization of the deal increases the number of wholly-owned Zentiva production
sites worldwide and will enable Zentiva to serve more people who are in daily
need of our high quality, affordable medicines.

"We are delighted to welcome the Ankleshwar team into our Zentiva family. We are
continuing to deliver strong growth at Zentiva and the completion of this
acquisition is an important milestone for our company," said Nick Haggar, Chief
Executive Officer of Zentiva. "The strength of our growing manufacturing network
and additional capacity means we can keep pace with the accelerating demand for
our medicines and increase our direct control over our supply chain to help
ensure continuous supply and rapid response to patient needs."

The transaction continues the flow of decisive growth moves made by Zentiva,
building on earlier acquisitions of Creo Pharma in the UK, Solacium in Romania
and the Central and Eastern European operations of Alvogen completed in April
2020. This latest acquisition in India runs in parallel to the ongoing multiple
multi-million Euro investments at Zentiva's flagship sites in Prague and
Bucharest.

"I am so proud that our Ankleshwar team will be part of an even stronger
Zentiva, integrated into the organization's long-term growth strategy," added
Ashwani Sood, Head of the Ankleshwar site . "We know demand for high quality and
affordable medicines is increasing and we look forward to contributing to
Zentiva's success on this journey."

The manufacturing site will be supported by a brand new Zentiva India affiliate
office in Mumbai.

About Zentiva

Zentiva is a producer of high-quality affordable medicines serving patients in
Europe and beyond. With a dedicated team of more than 4,700 people and a network
of production sites - including flagship sites in Prague, Bucharest and
Ankleshwar - Zentiva strives to be the champion of branded and generic medicines
in Europe to better support people's daily healthcare needs.

At Zentiva it is our aspiration that healthcare should be a right and not a
privilege. More than ever, people need better access to high quality affordable
medicines and healthcare. We work in partnership with physicians, pharmacists,
wholesalers, regulators and governments to provide the everyday solutions that
we all depend on.

Learn more about Zentiva on http://www.zentiva.com/ .

About Zentiva's Ankleshwar site

Established in 1987, the Ankleshwar manufacturing site has a chemistry and
biotechnology development center, and manufactures both intermediates and
pharmaceutical formulations. A large producer of tablets, the Ankleshwar site
manufactures more than 6 billion tablets annually.

Photo -

https://mma.prnewswire.com/media/1174951/Ankleshwar_production_site.jpg
Logo - https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg

Media Contact:

Mounira Lemoui
Head of CommunicationsZENTIVA GROUP, a.s.

U kabelovny 529/16, Dolní M?cholupy, 102 00 Prague 10
Cell: ([phone]
E-mail: [e-mail]

Additional content: https://www.presseportal.de/pm/132270/4610746
OTS: Zentiva